Emmanouil Spanoudakis
Overview
Explore the profile of Emmanouil Spanoudakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sachanas S, Vassilakopoulos T, Angelopoulou M, Papageorgiou S, Spanoudakis E, Bouzani M, et al.
Mediterr J Hematol Infect Dis
. 2025 Mar;
17(1):e2025014.
PMID: 40084092
New targeted therapies have revolutionized the treatment landscape in CLL. Biological features, patient characteristics and preferences and the safety profile of each treatment option should be taken into consideration for...
2.
Katodritou E, Kastritis E, Dalampira D, Fotiou D, Theodorakakou F, Delimpasi S, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39919999
Background: Despite treatment improvements a considerable proportion of newly diagnosed multiple myeloma (MM) patients experience early progressive disease (EPD) defined as progression or relapse in < 18 months following initial...
3.
Fotiou D, Badelita S, Katodritou E, Beksac M, Bila J, Spanoudakis E, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Jan;
PMID: 39890518
Background: Multiple myeloma (MM) is predominantly a disease of the elderly, but approximately 10% of patients are younger than 50 years at diagnosis. METHODS: This study aimed to investigate the...
4.
Kastritis E, Beksac M, Badelita S, Katodritou E, Bila J, Spanoudakis E, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Sep;
25(2):e71-e81.
PMID: 39304364
Background: Bortezomib, dexamethasone and cyclophosphamide (VCd) remains a popular regimen, due to its activity and low toxicity, while bortezomib, lenalidomide and dexamethasone (VRd) is widely used in US and Europe;...
5.
Kastritis E, Katodritou E, Badelita S, Bila J, Seval G, Cvetkovic Z, et al.
Leuk Lymphoma
. 2024 Aug;
65(13):2064-2067.
PMID: 39141607
No abstract available.
6.
Verrou E, Papageorgiou S, Bouzani M, Sevastoudi A, Triantafyllou T, Daiou A, et al.
Hematol Oncol
. 2024 Aug;
42(5):e3303.
PMID: 39105590
Involvement of female genital track (FGT) by diffuse large B cell lymphoma (DLBCL) represents an extremely rare diagnosis. Especially data regarding early-stage disease (i.e., IE, IIE) is very limited. Importantly,...
7.
Katodritou E, Dalampira D, Delimpasi S, Ntanasis-Stathopoulos I, Karaolidou F, Gkioka A, et al.
Am J Hematol
. 2024 Jul;
99(10):1897-1905.
PMID: 38953456
Central nervous system (CNS) involvement is a rare and aggressive complication of multiple myeloma (MM). We identified 54/4352 MM patients (1.2%), who developed CNS-MM between 2000 and 2022. A matched-control...
8.
Karatisidis L, Zagoridis K, Mprotsis T, Misidou C, Pentidou A, Vrachiolias G, et al.
Thromb Res
. 2024 May;
238:88-96.
PMID: 38696925
Introduction: Recommendations about proper anticoagulation in obese patients, body mass index (BMI) > 30 kg/m2, are not yet clearly defined. Obese patients were included in randomized controlled trials comparing new...
9.
Perrot A, Delimpasi S, Spanoudakis E, Frolund U, Belotti A, Oriol A, et al.
Leuk Lymphoma
. 2024 Mar;
65(6):833-842.
PMID: 38497533
Once-weekly carfilzomib at 56 mg/m plus immunomodulatory drugs and dexamethasone has shown efficacy and tolerability treating early relapsed/refractory multiple myeloma (RRMM). The phase 2 SELECT study (NCT04191616) evaluated efficacy/safety of...
10.
Papadakis S, Liapis I, Papadhimitriou S, Spanoudakis E, Kotsianidis I, Liapis K
J Clin Med
. 2024 Feb;
13(3).
PMID: 38337573
There is remarkable morphologic and genetic heterogeneity in acute myeloid leukemia (AML). In a small percentage of cases of AML, increased eosinophils and/or basophils are present in the bone marrow...